William Blair 和 Wedbush 下调了 2024 年第二季度 Neurocrine Biosciences 的盈利预测。 2024 Q2 Neurocrine Biosciences earnings estimates revised down by William Blair and Wedbush.

William Blair 和 Wedbush 的分析师已修改了对 Neurocrine Biosciences (NASDAQ:NBIX) 2024 年第二季度收益预测，分别预测每股 1.11 美元（低于 1.14 美元）和每股 1.18 美元（低于 1.25 美元）。 Analysts at William Blair and Wedbush have revised their Q2 2024 earnings estimates for Neurocrine Biosciences (NASDAQ:NBIX), forecasting $1.11/share (down from $1.14) and $1.18/share (down from $1.25), respectively. 对 Neurocrine 全年收益的普遍预期为每股 4.78 美元。 The consensus estimate for Neurocrine's full-year earnings stands at $4.78/share. 两家公司均维持该公司股票的“优于大盘”评级。 Both firms maintain an "Outperform" rating on the company's stock.